FORMULATION DEVELOPMENT AND EVALUATION OF SITAGLIPTIN-LOADED NANOSTRUCTURED LIPID CARRIERS FOR DIABETES MELLITUS

Abstract

Sitagliptin is dipeptidyl peptidase-4 (DPP-4) inhibitor which has extensive used for type 2 diabetes mellitus treatment by stimulating the level of incretion hormone to regulate glucose in the blood. The purpose of this research was to improve also evaluate nano lipid carriers (NLCs) of sitagliptin to increase its bioavailability, stability, also therapeutic potential of sitagliptin. Nine formulations (NLCs-F1 to NLCs-F9) were formulated using the hot homogenization technique using different concentrations of lipids. The characterization studies encompassed analysis of particle size, polydispersity index (PDI), zeta potential, drug entrapment efficiency, also in vitro drug release. NLCs-F4 and NLCs-F8, the optimally obtained, were of sizes 190nm and 351nm, correspondingly, and had PDI of 0.098 and 0.211, which indicated good mono dispersity. Entrapment efficiency was highest in NLCs-F4 (91.9±0.9) and NLCs-F8 (88.2±0.3). In vitro release studies of drug revealed biphasic release of drug with 82.49% and 80.46% drug release in 12 hours following Higuchi model drug release kinetics. From this study, it is evident that NLCs improve the bioavailability, stability, and controlled release of sitagliptin. The biocompatible lipidic drug delivery exhibits an easily scalable, solvent-free platform for pharma applications.